<a href="https://laohu8.com/S/CRSP">CRISPR Therapeutics AG</a> Announces Collaboration with Sirius <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Develop Next-Gen siRNA Therapy Targeting Thrombosis
CRISPR Therapeutics AG has announced a significant collaboration with Sirius Therapeutics, involving a Collaboration, Option and License Agreement. This partnership aims to advance the research, development, manufacture, and commercialization of innovative siRNA technology targeting Factor XI. A key focus of this collaboration is the co-development and commercialization of SRSD107, a next-generation siRNA designed to inhibit human coagulation factor XI, which is implicated in pathological thrombosis. This collaboration aims to reduce thrombotic events with minimal bleeding risk. The agreement includes options for CRISPR Therapeutics to exclusively license Sirius' siRNA technology for up to two additional targets, with potential milestone payments totaling $87.5 million. Both companies have committed to exclusivity in this field, prohibiting any siRNA-based advances targeting factor XI outside of this partnership.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-074428), on May 19, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。